ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

An Overall Evaluation of the Adjusted Version of Global Antiphospholipid Syndrome Score (aGAPSS) on Primary Obstetric Antiphospholipid Syndrome (POAPS) Patients

G. de Larrañaga1, F. Aranda1, S. Perés Wingeyer1, S. Udry1,2, S. Morales Perez3, C. Belizna4, J. Alijotas-Reig5, E. Esteve-Valverde3, D.S. Fernández Romero2, J. Latino2

1Hospital of Infectious Diseases F. J. Muñiz, CABA, Argentina, 2Acute Hospital Dr. Carlos G. Durand, CABA, Argentina, 3Althaia Healthcare University Network of Manresa, Barcelona, Spain, 4University Hospital Angers, Angers, France, 5Valld'Hebron University Hospital, Barcelona, Spain

Abstract Number: LPB0093

Meeting: ISTH 2021 Congress

Theme: Women Health » Pregnancy and Pregnancy Complications

Background: About 20% of POAPS patients, even under conventional treatment (CT) during pregnancy, still are at a high risk of suffering from obstetric morbidity.

Aims: To evaluate the clinical utility of aGAPSS to assess the risk of a new obstetric event on POAPS patients under CT during pregnancy.

Methods: 107 pregnancies from women with POAPS treated with CT were retrospectively evaluated [median age: 31 years; (28-36)]. CT included low dose aspirin and a prophylactic low molecular weight heparin/day. At the time of diagnosis, clinical and laboratory variables were evaluated and the aGAPSS was calculated. Treatment failure was defined as any of the following obstetric outcomes: early or late miscarriage, fetal loss, early severe pre-eclampsia and/or fetal growth restriction.

Results: Among the 107 pregnancies that were followed up, in 91 (85.1%) live births were achieved while 16 (14.9%) resulted in pregnancy loss: 12 (11.2%) miscarriages and 4 (3.7%) fetal losses. Fetal growth restriction in 7 (6.5%) and early severe pre-eclampsia in 4 (3.7%) pregnancies. Thus, CT failed in 23 pregnancies (21.5%).
The presence of triple positivity for antiphospholipid antibodies (aPL) [OR=8.410 (95% CI: 2.732-26.210), p<0.001], and an aGAPSS ≥7 [OR=3.664 (95% CI: 1.407-9.541), p=0.008] were associated with a higher chance of treatment failure. However, after multivariate analysis, only the triple positivity for aPL [OR=8.462 (95% CI: 2.732-26.210); p<0.0001] was found to be a strong risk factor independently associated with treatment failure.

APS Risk Factors Conventional treatment failure p
No (n= 84)  Yes (n=23)
aGAPSS value 5.8 (±2.99) 8.7 (±4.37)
Triple positivity of aPL 8.3% (7/84) 43.5% (10/23) p<0.001
aGAPSS≥7 26.2% (22/84) 56.6% (13/23) p=0.01
Cardiovascular Risk Factors: 
Hyperlipidemia 4.8% (4/84) 4.3% (1/23) NS
Arterial hypertension 8.3 % (7/84) 13.0 % (3/23) NS
Smoking habit 7.1 % (6/84) 17.4 % (4/23) NS
Obesity 8.3 % (7/84) 13.0 % (3/23) NS

Pregnancy outcomes on POAPS patients with CT according to the aGAPSS and other risk factors.

Conclusions: A high aGAPSS (≥7) would not be an independent risk factor for CT failure. In fact, the triple positivity of aPL would actually be an indicator of poorer response to CT and worse prognosis. Arterial hypertension and hyperlipidemia might have a significantly lesser contribution than triple positivity of aPL to the aGAPSS thus decreasing its potential as a prognostic marker.

To cite this abstract in AMA style:

de Larrañaga G, Aranda F, Perés Wingeyer S, Udry S, Morales Perez S, Belizna C, Alijotas-Reig J, Esteve-Valverde E, Fernández Romero DS, Latino J. An Overall Evaluation of the Adjusted Version of Global Antiphospholipid Syndrome Score (aGAPSS) on Primary Obstetric Antiphospholipid Syndrome (POAPS) Patients [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/an-overall-evaluation-of-the-adjusted-version-of-global-antiphospholipid-syndrome-score-agapss-on-primary-obstetric-antiphospholipid-syndrome-poaps-patients/. Accessed August 19, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/an-overall-evaluation-of-the-adjusted-version-of-global-antiphospholipid-syndrome-score-agapss-on-primary-obstetric-antiphospholipid-syndrome-poaps-patients/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley